These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36929411)

  • 41. Consultation on UTUC, Stockholm 2018 aspects of diagnosis of upper tract urothelial carcinoma.
    Fojecki G; Magnusson A; Traxer O; Baard J; Osther PJS; Jaremko G; Seitz C; Knoll T; Giusti G; Brehmer M
    World J Urol; 2019 Nov; 37(11):2271-2278. PubMed ID: 30915526
    [TBL] [Abstract][Full Text] [Related]  

  • 42. UroVysion® multiprobe FISH in the triage of equivocal urinary cytology cases.
    Bubendorf L; Piaton E
    Ann Pathol; 2012 Dec; 32(6):e52-6, 438-43. PubMed ID: 23244486
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation.
    Dimashkieh H; Wolff DJ; Smith TM; Houser PM; Nietert PJ; Yang J
    Cancer Cytopathol; 2013 Oct; 121(10):591-7. PubMed ID: 23801650
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multiple Fluorescences in Situ Hybridization Status in Excreted Urine Improve Diagnostic Efficacy for Upper Urinary Tract Urothelial Carcinomas.
    Tang F; Wang X; Liu T; Wang H; Wan Z; Fu Q; Zheng Z; Aersi M; Peng J
    Urol J; 2024 Mar; 21(2):107-113. PubMed ID: 38168059
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?
    Pierconti F; Martini M; Fiorentino V; Cenci T; Capodimonti S; Straccia P; Sacco E; Pugliese D; Cindolo L; Larocca LM; Bassi PF
    Urol Oncol; 2021 Feb; 39(2):131.e17-131.e21. PubMed ID: 32773233
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
    Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
    BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fluorescence in situ hybridization for detecting upper urinary tract tumors--a preliminary report.
    Akkad T; Brunner A; Pallwein L; Gozzi C; Bartsch G; Mikuz G; Steiner H; Verdorfer I
    Urology; 2007 Oct; 70(4):753-7. PubMed ID: 17991550
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bladder Chemoprophylaxis Following Ureterorenoscopy in Patients with Upper Tract Urothelial Carcinoma.
    Ferraris F; Raman JD; Yaber F
    Eur Urol Focus; 2022 Sep; 8(5):1253-1255. PubMed ID: 34340945
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictive value of MCM5 (ADXBLADDER) analysis in urine of men evaluated for the initial diagnosis of bladder cancer: A comparative prospective study.
    Anastasi E; Maggi M; Tartaglione S; Angeloni A; Gennarini G; Leoncini PP; Sperduti I; Di Lascio G; De Stefano V; Di Pierro GB; Del Giudice F; Busetto GM; De Berardinis E; Sciarra A
    Diagn Cytopathol; 2020 Nov; 48(11):1034-1040. PubMed ID: 32562513
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diagnostic Utility of Selective Upper Tract Urinary Cytology: A Systematic Review and Meta-analysis of the Literature.
    Potretzke AM; Knight BA; Vetter JM; Anderson BG; Hardi AC; Bhayani SB; Figenshau RS
    Urology; 2016 Oct; 96():35-43. PubMed ID: 27151340
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma.
    Simon CT; Skala SL; Weizer AZ; Ambani SN; Chinnaiyan AM; Palapattu G; Hafez K; Magers MJ; Kaffenberger SD; Spratt DE; Montgomery JS; Morgan TM; Udager AM; Lew M; Mehra R
    Hum Pathol; 2019 Apr; 86():76-84. PubMed ID: 30537495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up.
    Cancel-Tassin G; Roupret M; Pinar U; Gaffory C; Vanie F; Ondet V; Compérat E; Cussenot O
    World J Urol; 2021 Sep; 39(9):3329-3335. PubMed ID: 33770241
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Consultation on UTUC II Stockholm 2022: diagnostics, prognostication, and follow-up-where are we today?
    Sydén F; Baard J; Bultitude M; Keeley FX; Rouprêt M; Thomas K; Axelsson TA; Jaremko G; Jung H; Malm C; Proietti S; Osther PJS; Brehmer M
    World J Urol; 2023 Dec; 41(12):3395-3403. PubMed ID: 37540248
    [TBL] [Abstract][Full Text] [Related]  

  • 54. DNA methylation analysis in urinary samples: A useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group.
    Pierconti F; Rossi ED; Cenci T; Carlino A; Fiorentino V; Totaro A; Sacco E; Palermo G; Iacovelli R; Larocca LM; Bassi PF; Martini M
    Cancer Cytopathol; 2023 Mar; 131(3):158-164. PubMed ID: 36262084
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modified UroVysion scoring criteria increase the urothelial carcinoma detection rate in cases of equivocal urinary cytology.
    Huysentruyt CJ; Baldewijns MM; Rüland AM; Tonk RJ; Vervoort PS; Smits KM; van de Beek C; Speel EJ
    Histopathology; 2011 Jun; 58(7):1048-53. PubMed ID: 21707706
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Positive voided urine cytology predicts worse pathological findings of nephroureterectomy specimens in patients with upper tract urothelial carcinoma: does selective ureteral cytology have an additional efficacy?
    Sakano S; Inamoto T; Inoue R; Matsumoto H; Nagao K; Yamamoto Y; Azuma H; Matsuyama H
    Jpn J Clin Oncol; 2015 Oct; 45(10):968-72. PubMed ID: 26232447
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
    Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
    Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. UroVysion
    Iwata H; Sassa N; Kato M; Murase Y; Seko S; Kawanishi H; Hattori R; Gotoh M; Tsuzuki T
    Int J Clin Oncol; 2021 Jan; 26(1):178-185. PubMed ID: 32959230
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma.
    Pierconti F; Martini M; Cenci T; Fiorentino V; Gianfrancesco LD; Ragonese M; Bientinesi R; Rossi E; Larocca LM; Racioppi M; Bassi PF
    Urol Oncol; 2022 Mar; 40(3):108.e19-108.e25. PubMed ID: 34903453
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The value of the UroVysion® FISH assay in the risk-stratification of patients with "atypical urothelial cells" in urinary cytology specimens.
    Virk RK; Abro S; de Ubago JMM; Pambuccian SE; Quek ML; Wojcik EM; Mehrotra S; Chatt GU; Barkan GA
    Diagn Cytopathol; 2017 Jun; 45(6):481-500. PubMed ID: 28397365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.